Department of Clinical Laboratory Medicine, Institution of microbiology and infectious diseases, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Clinical Research Center for Myocardial Injury in Hunan Province, Hengyang, Hunan, China.
Biosci Trends. 2024 Mar 19;18(1):105-107. doi: 10.5582/bst.2024.01000. Epub 2024 Feb 8.
Lactylation of α-myosin heavy chain (α-MHC) has recently been reported to preserve sarcomeric structure and function and attenuate the development of heart failure. Specifically, lactylation enhanced the interaction of α-MHC with the sarcomeric protein Titin, thereby maintaining normal sarcomeric structure and myocardial contractile function. Furthermore, the administration of lactate or inhibition of lactate efflux potentially treats heart failure by restoring lactylation of α-MHC and the interaction of α-MHC with Titin. This finding highlights the significant role of α-MHC lactylation in myocardial diseases and presents a new therapeutic target for the treatment of heart failure.
α-肌球蛋白重链(α-MHC)的乳酰化作用最近被报道可以保护肌节结构和功能,并减轻心力衰竭的发展。具体来说,乳酰化作用增强了α-MHC 与肌节蛋白 Titin 的相互作用,从而维持正常的肌节结构和心肌收缩功能。此外,通过恢复α-MHC 的乳酰化和α-MHC 与 Titin 的相互作用,给予乳酸或抑制乳酸外排可能治疗心力衰竭。这一发现强调了α-MHC 乳酰化在心肌疾病中的重要作用,并为心力衰竭的治疗提供了一个新的治疗靶点。